Castle Biosciences

284 articles with Castle Biosciences

• Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

  3/18/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, shared new performance data from a novel, multi-center, independent cohort demonstrating how the independent risk-stratification of DecisionDx®-SCC test) can significantly improve metastatic risk predictions by complementing current staging systems.

• Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum

  3/14/2023

  Castle Biosciences, Inc. today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Wednesday, March 22, 2023, at 2:15 p.m. Eastern time.

• Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting

  3/10/2023

  Castle Biosciences, Inc. today announced that new data supporting its portfolio of skin cancer gene expression profile (GEP) tests will be showcased in one late-breaking oral presentation and three ePosters at the 2023 American Academy of Dermatology (AAD) Annual Meeting, being held March 17-21 in New Orleans.

• Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

  3/8/2023

  Castle Biosciences, Inc. announced the publication of a consensus panel report from the National Society for Cutaneous Medicine recommending use of gene expression profile testing in the clinical assessment and management of cutaneous melanoma.

• Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results

  2/28/2023

  Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31, 2022.

• Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing

  2/24/2023

  Castle Biosciences, Inc. today announced that its chief financial officer, Frank Stokes, was named to Finance & Investing’s Top 25 CFOs of Houston list for 2023.

• Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

  2/22/2023

  Castle Biosciences, Inc. today announced that new data on DecisionDx ® -Melanoma and the Company’s pipeline test for inflammatory skin diseases was presented at the recent 2023 Winter Clinical - Miami™ conference.

• Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines

  2/9/2023

  Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of data from a prospective, multicenter study, called DECIDE

• Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

  2/7/2023

  Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.

• Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year

  2/1/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that it has received a 2023 Top Workplaces USA award from Energage.

• Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023

  1/23/2023

  Castle Biosciences, Inc. today announced that the Company’s medical director, Matthew Goldberg, M.D., F.A.A.D., board-certified dermatologist and dermatopathologist, will present at the Precision Medicine World Conference (PMWC®) 2023, being held Jan. 25-27 in Santa Clara, California.

• Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio

  1/17/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii.

• Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results

  1/9/2023

  Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, announced certain unaudited preliminary performance results for the fourth quarter and full-year ended Dec. 31, 2022.

• Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory

  11/21/2022

  Castle Biosciences, Inc. today announced that the Accreditation Committee of the College of American Pathologists (CAP) has accredited its clinical laboratory facility in Pittsburgh.

• Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results

  11/17/2022

  Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of a study completed in collaboration with the Melanoma Research Foundation (MRF) in which most patients diagnosed with uveal melanoma (UM) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their UM tumor was at a high or low risk of metastasis.

• Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

  11/15/2022

  Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx ® -SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors.

• Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year

  11/14/2022

  Castle Biosciences, Inc. has been named a Houston Chronicle Top Workplace for the second year in a row.

• Castle Biosciences Announces Third Quarter 2022 Results

  11/2/2022

  Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2022.

• Castle Biosciences to Present at Upcoming November 2022 Investor Conferences

  11/1/2022

  Castle Biosciences, Inc. announced that the Company’s executive management is scheduled to present a company overview at the following investor conferences later this month: Credit Suisse 31st Annual Healthcare Conference on Nov. 9, 2022, at 12:50 p.m. Eastern time.

• Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma

  10/31/2022

  Castle Biosciences, Inc. (Nasdaq: CSTL) today announced the publication of real-world clinical utility data in Cancer Investigation showing that clinicians are ordering DecisionDx®-SCC for the intended high-risk cutaneous squamous cell carcinoma (SCC) patient population and that use of the test’s results can lead to risk-aligned changes in patient management strategies.